Cowen & Co. Maintains Their Buy Rating on Five Prime Therapeutics (FPRX)

In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRXResearch Report). The company’s shares closed last Monday at $4.42, close to its 52-week low of $3.18.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 7.2% and a 41.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, Nektar Therapeutics, and Mirati Therapeutics.

Five Prime Therapeutics has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.84 and a one-year low of $3.18. Currently, Five Prime Therapeutics has an average volume of 467.3K.

Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FPRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.